Matinas BioPharma Investor Relations Material
Latest events
Q2 2024
Matinas BioPharma
Q1 2025
14 May, 2025
Q4 2024
14 Apr, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Matinas BioPharma Holdings Inc
Access all reports
Matinas BioPharma Holdings Inc. is a biopharmaceutical company focused on developing lipid nanocrystal (LNC) delivery technology for the oral delivery of small molecules, gene therapies, and vaccines. The company's proprietary LNC platform aims to enhance the absorption and bioavailability of drugs, particularly those used to treat infectious diseases and cardiovascular conditions. The company is headquartered in Bedminster, New Jersey, and its shares are listed on the NYSE.
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
MTNB
Country
🇺🇸 United States